Triple negative’s: can we adjust the shot
Transcript of Triple negative’s: can we adjust the shot
![Page 1: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/1.jpg)
Arianna Pellegrino
Ospedale San Pietro Fatebenefratelli
Roma
Triple negative’s: can
we adjust the shot
with new
treatment?
![Page 2: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/2.jpg)
Agenda
● Prognosis and biology
● Adjuvant therapy
● Neoadjuvant therapy
● Post-Neoadjuvant therapy
● Minimal Residual Disease
![Page 3: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/3.jpg)
TNBC: Challanges and Opportunities
● TNBC lacks expression of ER, PR, HER2
● Accounts for 15% to 20% of all breast cancers
● Difficult-to-treat subtype that is highly heterogeneous
● Survival time is shorter than for other subtypes
● Because of lack of therapeutic targets, cytotoxic
chemotherapy is standard treatment
● Emerging data in TNBC management may affect
treatment strategies in the future
![Page 4: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/4.jpg)
Prognosis in early stage TNBC
![Page 5: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/5.jpg)
Biology of TNBC
![Page 6: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/6.jpg)
BRCA mutations and DNA repair
deficiency in TNBC
•80-90% of BRCA1 mutated
tumors are TNBC or basal-
like subtype
•‘’BRCA-ness’’ signatures
define addiotional TNBC
with DNA-repair deficiency
•Sensitivity to PARP
inhibitors and platinum
agents
![Page 7: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/7.jpg)
Immune infiltration predicts
response in TNBC
Pretherapeutic core biopsy samples from a total of 1058 patients (GeparDuo-GeparTrio)
High degree of correlation between stromal and intratumor lymphocytes
![Page 8: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/8.jpg)
Immune infiltration predicts
response in TNBC
![Page 9: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/9.jpg)
New context in TNBC adjuvant
setting
Strong prognostic role of sTILs in early-stage TNBC and excellent survival of patients with high sTILs after adjuvant chemotherapy and supports the integration
of sTILs in a clinicopathologic prognostic model for patients with TNBC
Loi S, JCO 2019
![Page 10: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/10.jpg)
Adjuvant Therapy: Chemotherapy is
still standard of care
Antrhacyclines, Taxanes, Dose-dense scheduling
![Page 11: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/11.jpg)
What will improve outcomes in early
TNBC?
•Not delayed initiation of adjuvant chemotherapy
•Platinum and/or PARP inhibitors
•Immunotherapy
![Page 12: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/12.jpg)
What will improve outcomes in early
TNBC?
•Not delayed initiation of adjuvant chemotherapy
•Platinum and/or PARP inhibitors
•Immunotherapy
![Page 13: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/13.jpg)
Delayed initiation of adjuvant
chemotherapy
![Page 14: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/14.jpg)
Delayed initiation of adjuvant
chemotherapy
![Page 15: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/15.jpg)
What will improve outcomes in early
TNBC?
•Not delayed initiation of adjuvant chemotherapy
•Platinum and/or PARP inhibitors
•Immunotherapy
![Page 16: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/16.jpg)
Platinum agents in early stage TNBC
![Page 17: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/17.jpg)
Platinum agents in early stage TNBC
![Page 18: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/18.jpg)
To whom shall we give a platinum
![Page 19: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/19.jpg)
What will improve outcomes in early
TNBC?
•Not delayed initiation of adjuvant chemotherapy
•Platinum and/or PARP inhibitors
•Immunotherapy
![Page 20: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/20.jpg)
Targeting DNA damage repair with
PARP inhibitors
![Page 21: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/21.jpg)
Homologous recombination
deficiency in TNBC and
chemotherapy response
![Page 22: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/22.jpg)
To whom shall we give a platinum?
![Page 23: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/23.jpg)
Ongoing neo/adjuvant PARP/platinum trials
![Page 24: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/24.jpg)
What will improve outcomes in early
TNBC?
•Not delayed initiation of adjuvant chemotherapy
•Platinum and/or PARP inhibitors
•Immunotherapy
![Page 25: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/25.jpg)
I-SPY 2 TRIAL: Pembro 4 Arm
Schema
![Page 26: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/26.jpg)
Pembrolizumab graduated in all
HER2- signatures: 3-Fold increase in
pCR in both HR+/HER2- and TNBC
![Page 27: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/27.jpg)
GeparNUEVO Study Design
![Page 28: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/28.jpg)
GeparNUEVO Primary endpoint
![Page 29: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/29.jpg)
![Page 30: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/30.jpg)
ISPY2 and GeparNUEVO
![Page 31: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/31.jpg)
Ongoing neo/adjuvant trials with PD-
1/PD-L1 inhibitors
![Page 32: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/32.jpg)
Ongoing neo/adjuvant trials with PD-
1/PD-L1 inhibitors
I-SPY2: De-escalating chemotherapy-Pembro 8 Arm
I-SPY2: Durva/Olaparib
![Page 33: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/33.jpg)
![Page 34: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/34.jpg)
Post-neoadjuvant therapy:
Capecitabine in TNBC
![Page 35: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/35.jpg)
Post-neoadjuvant therapy:
Immunotherapy in TNBC
![Page 36: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/36.jpg)
Minimal Residual Disease: the Next
Frontiers ● Detection
Circulating tumor DNA (blood)
CTCs (blood)
DTCs (bone marrow)
● Monitoring
Sensitivity/specificity/prognostic significance
Results disclosure to patients
● Intervention
Do TNBC have a dormant phase?
Best intervention for micrometastatic disease
Does modulation of surrogate lead to improved survival?
![Page 37: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/37.jpg)
![Page 38: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/38.jpg)
![Page 39: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/39.jpg)
Summary: Challenges in treating
early TNBC
● Disease remains high risk, especially if residual disease
after NACT
● Optimizing chemotherapy with platinum has some value
in some patients – at a price
● Novel therapies improve short-term outcomes, but long-
term benefits not yet clear
➢ PARP inhibitors
➢ Immunotherapy
![Page 40: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/40.jpg)
Summary: Challenges in treating
early TNBC
● Post-neoadjuvant trials provide opportunity to escalate
therapy in poor responders
➢ Smaller trials, faster answers
➢ Need biomarkers for treatment selection and time to
assess benefits
● Detection and targeting of minimal residual disease is
next frontier to improve outcomes for all patients with
TNBC
![Page 41: Triple negative’s: can we adjust the shot](https://reader033.fdocuments.us/reader033/viewer/2022042206/6258e54288af862189613997/html5/thumbnails/41.jpg)